Navidea Biopharmaceuticals filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025, signaling the company is seeking to restructure its finances.
Navidea Biopharmaceuticals Filed Chapter 11 Bankruptcy
According to PacerMonitor, Navidea Biopharmaceuticals, Inc., at 4100 Horizons Drive, Suite 205, Columbus, OH 43220, filed Chapter 11 bankruptcy protection on October 1, 2025. Counsel Joseph C. Barsalona II from Pashman Stein Walder Hayden, P.C., is representing the case in the Delaware Bankruptcy Court.
The company lists between 100 and 199 creditors, with assets estimated at $1 million to $10 million and liabilities between $10 million and $50 million. The case is designated as Subchapter V small business, and further filings and restructuring meetings are being scheduled by the court.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals is a clinical-stage biopharmaceutical company developing precision immunodiagnostics and immunotherapeutics. The company’s proprietary Manocept platform targets disease-related macrophages to improve diagnostic precision and support advanced treatments. Navidea’s research focuses on conditions including cancer, autoimmune disorders, and inflammatory diseases.
In addition to developing new therapies, Navidea has pursued strategic partnerships, including the 2017 sale of North American rights to Lymphoseek, which generated significant upfront revenue. Navidea remains at the crossroads of state-of-the-art immunology and real-life medical use.
Through Chapter 11, Navidea aims to address financial and operational challenges, including regulatory compliance and liquidity concerns. The restructuring process will involve negotiations with creditors and court approval as the company works to reposition its biopharma operations.
